NCT03989037: A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer |
|
|
| Completed | 3 | 580 | RoW | SIBP-01, Herceptin Biosimilar, Herceptin, Trastuzumab, Docetaxel, Docetaxel Injection, Carboplatin, PARAPLATIN®，Carboplatin Injection | Shanghai Institute Of Biological Products, Fudan University | HER2-positive Early Breast Cancer | 04/23 | 04/23 | | |
